Search

The suitability of the comet assay for quantifying DNA repair capacity at individual level was studied following the kinetics of nucleotide excision repair (NER) in human lymphocytes from four healthy donors, at various time steps after a single dose of UVC. A significant increase of DNA migration was seen as soon as 20min after UV exposure, reaching the peak within 60-90min. Afterwards, a rapid decline was observed, approaching the basal level at 180-240min. The increase could be ascribed to excision activity, while the reduction to gap filling and rejoining, as demonstrated by the effects of phase-specific inhibitors, novobiocin and aphidicolin. Therefore, the comet assay should allow following the biphasic kinetics of NER. Wide inter-individual differences were observed, although repeated tests on the same donor cells revealed a large experimental variation. To quantitatively compare the individual patterns, a mathematical model was developed that adequately fitted the experimental results and estimated appropriate descriptors for each phase and for each donor. A second approach was also used to directly compare the distributions of damaged cells and to assess the differences between donors and between experiments visualizing them as reciprocal distances on a two-dimensional space computed with a principal component analysis (PCA). The results confirmed the inter-individual differences, but also the strong influence of experimental factors of the comet assay. The two approaches provided the means of accurately comparing DNA repair kinetics at individual level, taking also into account the experimental variability which poses serious doubts on the suitability of the comet assay. Nevertheless, since this methodology allows a detailed analysis of repair kinetics and it is potentially very useful for identifying individual with reduced repair capacity, further efforts have to be addressed to improve the reproducibility of the comet assay.

Clinical evidence suggests that deprenyl may slow progression of Parkinson's disease, although mechanisms underlying this putative neuroprotective action remain poorly understood. To address this issue, we studied deprenyl in 12 parkinsonian patients using a singleblind, placebocontrolled, crossover design. After 1 month, deprenyl 10 mgd decreased the optimal levodopa requirement by 24 oral and 16 intravenous. Levodopainduced dyskinesias were prolonged by 430, and antiparkinsonian action by 44. Mood improved by 47. One month after withdrawing deprenyl, effects on dyskinesias and mood had yet to return to baseline. There was no change in activities of circulating glutathione peroxidase, glutathione reductase, glutathione transferase, superoxide dismutase, and catalase, nor in levels of lipid peroxide and vitamin E. Deprenyl also failed to modify CSF levels of total glutathione and activities of glutathione peroxidase or superoxide dismutase. These effects on levodopa pharmacodynamics and mood complicate the interpretation of available investigations of deprenyl's neuroprotective action and increase the risk of adverse effects of levodopa.

We administered the partial dopamine agonist terguride under controlled conditions to patients with Parkinson's disease (PD), both as monotherapy and in conjunction with intravenous levodopa. Terguride produced a dose-dependent decrease in levodopa-induced dyskinesias (up to 53) in seven patients without concomitant worsening of parkinsonism, and had no significant antiparkinsonian effect when administered alone. Partial dopamine agonists may hold some promise in the adjuvant therapy of patients with advanced PD.